News

The European Commission (EC) has approved Forxiga (dapagliflozin) for use in type-1 diabetes (T1D) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin alone does…
Read More...

Aimmune Therapeutics announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral…
Read More...

MilliporeSigma officially opened its new M Lab Collaboration Center in Molsheim, France. The center is MilliporeSigma's first in Europe and ninth worldwide, providing biopharmaceutical…
Read More...

GlaxoSmithKline plc announced further positive data from the DREAMM-1 study of patients with relapsed/refractory multiple myeloma who received GSK2857916, an investigational anti-B-cell…
Read More...

PARIS & Vivet Therapeutics and Pfizer announced that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and…
Read More...

Conatus Pharmaceuticals Inc. announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and…
Read More...

Biologics by McKesson continues to expand its capabilities as a specialty pharmacy expert in oncology and complex conditions through a new exclusive distribution agreement. After making…
Read More...

Merck announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector…
Read More...

Petra Pharma Corporation announced that it has secured a global license from Takeda Pharmaceutical Company Limited to develop, manufacture and commercialize serabelisib and two…
Read More...

HemoShear Therapeutics, LLC announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop additional novel therapeutics for liver…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial…
Read More...

Merck and NGM Biopharmaceuticals announced that Merck has exercised its option to extend the research phase of the companies’ broad, strategic collaboration for an additional two-year…
Read More...

Alexion Pharmaceuticals and Affibody AB announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development,…
Read More...

The Mundipharma network of independent associated companies is pleased to launch the type-2 diabetes mellitus (T2DM) treatments Invokana (canagliflozin) and Vokanamet (canagliflozin,…
Read More...

WuXi Biologics announced that it has received EMA GMP certificates for the production of Trogarzo at its cGMP Drug Substance (DS) and Drug Product (DP) manufacturing facilities in Wuxi…
Read More...

EastGate Biotech Corp., a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes,…
Read More...

Allergan plc announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam),…
Read More...

Sage Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO…
Read More...

TESARO, an oncology-focused business acquired by GlaxoSmithKline plc, announced the presentation of data from the Phase 1/2 GARNET study evaluating dostarlimab in women with recurrent…
Read More...

Evotec AG and The Global Antibiotic Research and Development Partnership are today announcing the formation of a new strategic public-private partnership to tackle the growing threat of…
Read More...